Skip to main content
Premium Trial:

Request an Annual Quote

Proventys Raises $5.65M in Private Financing; Inks McKesson Alliance

NEW YORK (GenomeWeb News) – Proventys said this week that it has secured $5.65 million in a Series A1 financing led by venture capital firm Burrill & Company.
The Durham, NC-based firm also said that it has signed an agreement with healthcare information technology firm McKesson, under which McKesson will incorporate Proventys’ risk prediction modules into its clinical decision support solutions. Concurrent with that agreement, the firm named Marc Owen, executive vice president of corporate strategy and business development at McKesson, to its board of directors.
“McKesson is uniquely positioned with proven clinical decision support tools that can provide the ideal platform for bringing Proventys’ advanced knowledge solutions to the point of care where they can make a real difference in clinical decision making and patient outcomes,” Owen said in a statement.
Proventys also said that it has named Timothy Thompson, formerly managing director of business development at Aetna, as its new president and CEO. Ralph Snyderman, founder and chairman of the firm, will remain chairman.
Proventys is developing risk-prediction tools using clinical data and biomarkers that it believes will enable more effective, targeted approaches to medicine.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.